乳糖凝用于新生儿低血糖症 (糖婴儿研究):一个随机,双盲,安慰剂对照试验
Deborah L Harris1, Philip J Weston2, Matthew Signal3
1Newborn Intensive Care Unit, Waikato District Health Board, Hamilton, New Zealand; Liggins Institute, University of Auckland, Auckland, New Zealand.
Lancet (London, England)
|October 1, 2013
概括
德克斯特凝有效地治疗风险婴儿的新生儿低血糖症,与安慰剂相比,减少治疗失败. 这种简单的干预提供了一个有希望的第一线方法来管理新生儿低血糖.
科学领域:
- 新生儿医学 新生儿医学
- 儿科内分泌学 儿科内分泌学
背景情况:
- 新生儿低血糖症是一种常见的疾病,也是婴儿脑损伤的可预防原因.
- 关于德克斯特凝治疗新生儿低血糖症的疗效的证据有限.
研究的目的:
- 评估德克斯特凝与单独养相比,在风险婴儿中逆转新生儿低血糖的有效性.
主要方法:
- 一项随机,双盲,安慰剂对照试验与237名风险婴儿 (35-42周怀孕,<48小时) 进行.
- 婴儿接受了40%的乳糖凝 (200 mg/kg) 或安慰剂凝,治疗失败被定义为血糖<2.6 mmol/L两次尝试后.
主要成果:
- 与安慰剂相比,乳糖凝显著降低了治疗失败率 (14%对24%,RR0.57,p=0.04).
- 没有报告严重的不良事件;安慰剂组的三个婴儿有一个低血糖值 (0.9 mmol/L).
结论:
- 德克斯特凝是一种廉价和简单的新生儿低血糖症的第一线治疗方法,用于晚期早产和满期婴儿.
- 建议在出生后的前48小时考虑使用乳糖凝来治疗低血糖症.
相关概念视频
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...


